FUJIFILM Corporation has announced that it has expanded its manufacturing capacity at FUJIFILM Toyama Chemical Co., Ltd. to significantly increase production of its influenza antiviral drug “Avigan® Tablet” (generic name: favipiravir) for treating patients with COVID-19.
To further boost the supply of Avigan, Fujifilm is allocating additional capacity at its FUJIFILM Wako Pure Chemical Co., Ltd. facility in Japan, for production of pharmaceutical intermediates used to manufacture Avigan.
Fujifilm expects to progressively increase the monthly production of Avigan up to 100,000 treatment courses* by July 2020, approximately 2.5 times more compared to the beginning of March, when the company first began its current production run. In addition, Fujifilm plans to further accelerate production up to 300,000 treatment courses* by September 2020...
Full text GMPnews.Net